ALEXANDRIA, Va., June 19 -- United States Patent no. 12,332,251, issued on June 17, was assigned to Merck Patent GmbH (Darmstadt, Germany).
"Metabolic biomarkers for predicting responsiveness to FGF-18 compound" was invented by Christoph H. Ladel (Darmstadt, Germany), Hans Guehring (Geisenheim, Germany), Anne-Christine Bay-Jensen (Copenhagen, Denmark), Morten Karsdal (Copenhagen, Denmark) and Per Qvist (Copenhagen, Denmark).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blo...